Literature DB >> 20847875

Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?

Brigitte Mlineritsch1.   

Abstract

Breast cancer remains the most prevalent cancer diagnosed in women worldwide. The number of effective treatments for breast cancer is on the rise, however, the benefit from specific treatments to individual patients and the adverse events experienced vary considerably. Efficacy and safety of anticancer therapies may depend on tumor, treatment, and host characteristics. Advances in the adjuvant chemotherapy of operable breast cancer have come from the introduction of effective agents and the application of the principles of combination chemotherapy. Attempts to advance these principles by substantial escalation of drug dosage have proven unsuccessful with a potentially higher rate of side effects. Another concept to increase efficacy is dose density, the administration of drugs with shortened intertreatment interval, and sequential therapy. The dose-dense concept improved clinical outcome significantly and was not accompanied by an increase in toxicity.

Entities:  

Year:  2009        PMID: 20847875      PMCID: PMC2931003          DOI: 10.1159/000222333

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  27 in total

1.  Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Authors:  C Hudis; A Seidman; J Baselga; G Raptis; D Lebwohl; T Gilewski; M Moynahan; N Sklarin; D Fennelly; J P Crown; A Surbone; M Uhlenhopp; E Riedel; T J Yao; L Norton
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

Authors:  M J Piccart; A Di Leo; M Beauduin; A Vindevoghel; J Michel; C Focan; A Tagnon; F Ries; P Gobert; C Finet; M T Closon-Dejardin; J P Dufrane; J Kerger; F Liebens; S Beauvois; S Bartholomeus; S Dolci; J P Lobelle; M Paesmans; J M Nogaret
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

6.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Authors:  J Bergh; T Wiklund; B Erikstein; E Lidbrink; H Lindman; P Malmström; P Kellokumpu-Lehtinen; N O Bengtsson; G Söderlund; G Anker; E Wist; S Ottosson; E Salminen; P Ljungman; H Holte; J Nilsson; C Blomqvist; N Wilking
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

7.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

Authors:  B Fisher; S Anderson; D L Wickerham; A DeCillis; N Dimitrov; E Mamounas; N Wolmark; R Pugh; J N Atkins; F J Meyers; N Abramson; J Wolter; R S Bornstein; L Levy; E H Romond; V Caggiano; M Grimaldi; P Jochimsen; P Deckers
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

8.  Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

Authors:  Halle C F Moore; Stephanie J Green; Julie R Gralow; Scott I Bearman; Danika Lew; William E Barlow; Clifford Hudis; Antonio C Wolff; James N Ingle; Helen K Chew; Anthony D Elias; Robert B Livingston; Silvana Martino
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

9.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

Authors:  G Bonadonna; M Zambetti; P Valagussa
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

10.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.